Darolutamide Extends Survival in Metastatic Prostate Cancer - NCI

Adding darolutamide (Nubeqa) to ADT and docetaxel improves survival in hormone-sensitive metastatic prostate cancer, results from the ARASENS trial show.

Nonmetastatic Castration-Resistant Prostate Cancer: Current

Cancers, Free Full-Text

Phase 1 study of darolutamide (ODM-201): a new-generation androgen

Selected Ongoing Trials With Darolutamide In Prostate Cancer

Frontiers YIV-818-A: a novel therapeutic agent in prostate

Darolutamide and Survival in Metastatic, Hormone-Sensitive

Efficacy and safety of darolutamide in Japanese patients with

Darolutamide: New Standard of Care in Nonmetastatic CRPC?

Prostate Cancer Treatment Market Size and Share

Frontiers Exploring anti-androgen therapies in hormone dependent

Prostate cancer Nature Reviews Disease Primers

PDF] Darolutamide For Castration-Resistant Prostate Cancer

Treatment and trials in non-metastatic castration-resistant